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Abstract
Purpose: The introduction of stereotactic radiotherapy has raised concerns regarding the use of the linear-quadratic (LQ) model
for predicting radiation response for large fractional doses. To partly address this issue, a transition dose D* below which the LQ
model retains its predictive strength has been proposed. Estimates of D* which depends on the , β, and D0 parameters are much
lower than fractional doses typically encountered in stereotactic radiotherapy. D0, often referred to as the final slope of the cell
survival curve, is thought to be constant. In vitro cell survival curves generally extend over the first few logs of cell killing, where
D0-values derived from the multi-target formalism may be overestimated and can lead to low transition doses. Methods:
D0-values were calculated from first principles for each decade of cell killing, using experimentally-determined  and β param-
eters for 17 human glioblastoma, neuroblastoma, and prostate cell lines, and corresponding transition doses were derived. Results:
D0 was found to decrease exponentially with cell killing. Using D0-values at cell surviving fractions of the order of 10-10 yielded
transition doses ~3-fold higher than those obtained from D0-values obtained from conventional approaches. D* was found to
increase from 7.84 ± 0.56, 8.91 ± 1.20, and 6.55 ± 0.91 Gy to 26.84 ± 2.83, 23.95 ± 2.03, and 22.49 ± 2.31 Gy for the glioblastoma,
neuroblastoma, and prostate cell lines, respectively. Conclusion: These findings suggest that the linear-quadratic formalism might
be valid for estimating the effect of stereotactic radiotherapy with fractional doses in excess of 20 Gy.
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Introduction
The  and  parameters of the linear-quadratic (LQ) model
are routinely used to estimate the biologically effective dose
(BED) which has long been very valuable in making com-
parisons between the effects of different dose-fractionation
schemes.1-6 Following the introduction of stereotactic and
hypofractionated radiotherapy over two decades ago, re-
searchers have questioned the appropriateness of using the
LQ model to predict treatment outcome, especially when
large fractional doses are administered.7-12 The LQ model has
been the preferred algorithm for evaluating the effects of
radiotherapy with doses per fraction  10 Gy for decades, but
with the advent of stereotactic radiotherapy it has been sug-
gested that the model may not be valid when doses exceeding
15 Gy are acutely delivered.13 The overriding reason for this
concern is that it predicts much higher levels of cell kill than
those observed in the clinic and in vivo systems.7 Using both
single-cell and spheroid cultures, Iwata et al. have shown that
the use of the LQ model to convert doses of hypofractionation
schedules to single doses can result in significant underesti-
mation of the potency of hypofractionated radiation treat-
ment.11 A similar conclusion was reached by these investiga-
tors in studies on a murine tumor model.14 Notably, these
investigations demonstrated that BED values calculated using
the LQ formalism can be as low as 30% of those that are ac-
tually measured. More recently, Iwata et al. compared the LQ
model with the repairable-conditionally-repairable and mul-
ti-target models and concluded that the former should not be
used for high dose per fraction radiotherapy for similar rea-
sons.15 However, the predictive capacity of the LQ formalism
appears to be dependent on tissue and tumor type; and it has
been suggested that for certain tissues, use of the LQ model to
evaluate hypofractionated and stereotactic radiotherapy may
be valid for fractional doses of the order of 18 - 20 Gy.4,16 The
LQ formalism has been successfully used in the clinic for the
evaluation of biologically effective doses for tumor control
and normal tissue complication for fractional doses of 5 - 27
Gy.17-20 Clearly, there is controversy regarding the clinical
application of the LQ formalism when single or a few large
fractional doses of radiation are used.9-12
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Given that fractional doses exceeding 15 Gy may be used in
stereotactic radiotherapy21-24, there has been a recent increase
in the desire to re-evaluate the applicability of the LQ model
in radiotherapy regimens employing large doses per fraction.
To address potential shortcomings of the LQ model in its
utility in stereotactic and hypofractionated radiotherapy,
some investigators have suggested modifications to the LQ
model for high fraction doses.7, 10, 13, 25, 26 Although these ex-
tensions to the LQ model seem to have improved capacity to
fit experimental data at high doses, Fowler cautioned re-
searchers not to totally abandon the model on the grounds of
its failure to predict radiosensitivity at high levels of cell kill.27
One cell survival parameter that has not enjoyed the same
level of popularity as the  and  coefficients in predicting
clinical outcome is D0 which is an indicator of the behavior of
cell survival curves at high acute radiation doses. Recently,
the importance of D0 in estimating the dose at which the LQ
model starts to depart from the modified LQ (MLQ) model as
proposed by Guerrero and Li was highlighted.7, 10 The MLQ
model uses the well-defined  and  parameters and retains
the simplicity of the LQ model.7 Also, the MLQ model in-
troduces a shift parameter, , in the dose protraction factor
from which the dose, D*, at which the LQ model begins to
deviate from mechanism-based models like the le-
thal-potential lethal model can be derived.7 In addition to 
and ,  depends on D0. The latter is often referred to as the
reciprocal of the final slope of the cell survival curve, and
should be a cell-type specific constant at high doses. Deter-
mination of D0 from in vitro cell survival data, using either
the LQ or the multi-target model, has typically been possible
over the first 3 logs of cell kill giving D0 values of 1.0 – 3.7
Gy.1, 28-35 It is conceivable that values of D0 derived at higher
levels of cell kill may differ markedly from those obtained in
the first few logs of cell kill, and can have a significant impact
on the magnitude of the -parameter. Hence, the role of D0 in
determining the appropriateness of the LQ formalism in
modeling radiation response in stereotactic radiotherapy
needs further evaluation.
In the following, data for 17 cancer cell lines spanning a wide
range of radiosensitivities 36-38, were used to test whether D0,
as originally defined, is indeed independent of the level of cell
kill. The implications of a potential dependence of D0 on the
extent of cell kill on the strength of the LQ model as a pre-
dictor of radiosensitivity at high radiation absorbed doses are
further discussed.
Methods and Materials
Estimation of D0 from the multi-target model
From the multi-target formalism and for sufficiently large
radiation absorbed doses, the cell surviving fraction, SD, is
related to radiation absorbed dose, D, by:− ( ) = (1⁄ ) + (1)
where, k is a cell type-dependent constant. D0-values were
derived from the slope of a linear regression fit according to
Equation (1) for SD ≤ 0.1 and absorbed doses not greater than
10 Gy, using cell survival data for 17 cell lines from three
different cancer types 36-38, and were subsequently used to
calculate transition doses for comparison with those deter-
mined from the LQ formalism.
Derivation of D0 and transition dose from LQ model
According to the linear-quadratic model, the surviving frac-
tion SD of a population of cells exposed to an absorbed radia-
tion dose, D, is given by the equation:= ( ) (2)
where,  and  are the coefficients of the linear and quadratic
components of cell killing, respectively. Equation (2) may be
rearranged as a quadratic function of the form:+ + = 0 (3)
Solving Equation (3), the absorbed dose corresponding to a
surviving fraction of SD is given by:= ( ) (4)
By definition, the D0 is the dose required to decrease the
surviving fraction from 1.0 to 0.37, 0.1 to 0.037, 0.01 to
0.0037, and so on.39 Therefore, D0 may be calculated from the
doses determined in Equation (4) as follows:= . − . , ℎ 1. − . , ℎ 2. − . , ℎ 3 (5)
Similarly, D0 can be calculated for up to 10 or more logs of cell
killing as may be required to ensure control of a tumor con-
taining < 1010 malignant cells.30 D0 is often referred to as the
“final slope” of the cell survival curve, and is thought to be
constant when derived beyond the “shoulder” of the curve
regardless of the log of cell killing. To interrogate this notion,
the relationship between D0 and the level of cell killing was
evaluated for 17 human cell lines of different origins (Table
1). In this study, data for 6 glioblastoma, 4 neuroblastoma, and
7 prostate cell lines were used.36-38 Experimentally deter-
mined  and  coefficients were used to calculate D0, as de-
scribed in Equations (4) and (5). For each cell line,  and 
were derived from 6 - 7 cell survival data points within the
absorbed dose range of 0 – 10 Gy. The obtained D0-values
were then plotted against the nth log of cell killing, and fitted
to a two-phase exponential decay function of the form:= + + (6)
where a, b and c are cell line-specific constants, and D0 decays
with rate constants k1 and k2. The dose protraction shift pa-
rameter, , can be determined from D0, as follows7:
 =  (7)
from which the transition dose D* can be derived as the re-
ciprocal of .7
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TABLE 1: Summary of parameters derived from the multi-target and linear-quadratic models for seventeen human cell lines.
Multi-target model Linear-quadratic model
Cell line  (Gy-1)#  (Gy-2)# D0 (Gy)§  (Gy-1)§ D* (Gy)§ D0 (Gy)§  (Gy-1)§ D* (Gy)§
Glioblastoma36,37
G44 0.17±0.03 0.03±0.00 1.61±0.27 0.133±0.040 7.52±2.24 0.64±0.03 0.043±0.004 23.25±1.87
G112 0.21±0.03 0.01±0.00 2.41±0.22 0.098±0.032 10.25±3.39 0.99±0.05 0.025±0.003 40.19±4.04
G120 0.18±0.03 0.04±0.00 1.21±0.02 0.124±0.007 8.08±0.42 0.55±0.03 0.049±0.004 20.36±1.60
G62 0.20±0.05 0.03±0.01 1.54±0.06 0.134±0.067 7.49±3.75 0.59±0.03 0.040±0.006 25.15±3.54
G28 0.15±0.01 0.02±0.00 2.55±0.01 0.165±0.008 6.05±0.29 0.87±0.05 0.040±0.003 24.95±1.74









SK-N-BE(2c) 0.24±0.03 0.03±0.01 1.22±0.07 0.104±0.014 9.66±1.27 0.58±0.03 0.041±0.007 24.66±4.08
SK-N-SH 0.66±0.11 0.02±0.01 0.99±0.02 0.114±0.036 8.76±2.72 0.64±0.02 0.045±0.008 22.32±3.83
KELLY 0.77±0.14 0.01±0.01 1.00±0.08 0.087±0.037 11.49±4.84 0.74±0.01 0.034±0.005 29.19±3.92
SHSY5Y 0.54±0.07 0.02±0.01 1.30±0.15 0.175±0.054 5.73±1.79 0.76±0.02 0.051±0.007 19.61±2.85
Mean±SEM
CV
1.13±0.08 0.120±0.019 8.91±1.20 0.68±0.04 0.043±0.004 23.95±2.03
13.88% 12.04%
Prostate 37,38
0.27±0.02 0.27±0.02 0.02±0.00 1.71±0.09 0.127±0.037 7.87±2.30 0.73±0.04 0.036±0.003 27.63±2.14
0.29±0.05 0.29±0.05 0.02±0.01 1.50±0.07 0.106±0.035 9.42±3.13 0.80±0.04 0.042±0.006 23.95±3.27
0.38±0.07 0.38±0.07 0.02±0.01 1.47±0.12 0.133±0.039 7.51±2.19 0.73±0.03 0.040±0.006 24.73±3.85
0.49±0.03 0.49±0.03 0.01±0.00 1.73±0.09 0.227±0.066 4.40±1.27 0.95±0.02 0.036±0.003 28.01±2.67
0.61±0.02 0.61±0.02 0.01±0.00 1.31±0.02 0.130±0.073 7.69±4.28 0.90±0.01 0.040±0.003 25.07±1.95
0.63±0.04 0.63±0.04 0.01±0.01 1.48±0.04 0.438±0.192 2.28±1.00 1.15±0.02 0.085±0.009 11.73±1.28
0.24±0.05 0.24±0.05 0.06±0.01 0.96±0.07 0.150±0.049 6.68±2.16 0.46±0.02 0.061±0.003 16.31±1.68
Mean±SEM
CV
1.45±0.10 0.187±0.044 6.55±0.91 0.81±0.08 0.049±0.007 22.49±2.31
18.00% 26.76%
# Errors were derived from data fitted to LQ model; β-errors less than 0.005 were set to zero; §errors were calculated using appropriate error
propagation formulae.
FIG. 1: Plots of the natural logarithm of surviving fraction (for SD ≤ 0.1), from historic studies, against absorbed dose for human (a) glioblastoma;
(b) neuroblastoma and (c) prostate cell lines.36-38 Reciprocals of slopes of regression fits represent D0 as derived from the multi-target formalism
(Equation (1)).
Results
The data presented in Figure 1 represent linear regression fits
of the natural logarithm of surviving fraction (for SD ≤ 0.1)
plotted against absorbed dose. D0-values derived from the
slopes of the regression fits according to Equation (1) for the
glioblastoma, neuroblastoma and prostate cell lines emerged
as 1.80 ± 0.22 (range: 1.21 – 2.55), 1.13 ± 0.08 (range: 0.99 –
1.30) and 1.45 ± 0.10 (range: 0.96 – 1.73) Gy, respectively.
D0-values derived from  and  parameters, as described in
Equations (4) and (5), are plotted as a function of the log of
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cell killing for the glioblastoma cells in Figure 2. For com-
parison, D0-values determined from Figure 1 according to the
multi-target formalism for all cell lines are also presented.
D0-values derived from the LQ model were found to decrease
significantly over cell killing, diminishing from 3.49 ± 0.30
Gy in the first log of cell inactivation to 0.72 ± 0.07 Gy in the
10th log of cell killing (Figure 2).
FIG. 2: Plot of D0, derived from LQ parameters, as a function of the
decade of cell killing in which D0 is derived for 6 human glioblastoma
cell lines. D0 is calculated as the dose required to reduce the cell
surviving fraction from: 1.0 to 0.37 (for the first decade of cell kill-
ing), 0.1 to 0.037 (for the second decade of cell killing), 0.01 to 0.0037
(for the third decade of cell killing), and so on, using historic  and β
parameters.36, 37 Large symbols represent D0-values derived from the
multi-target formalism.
FIG. 3: Plot of D0, derived from LQ parameters, as a function of the
decade of cell killing in which D0 is derived for 4 human neuroblas-
toma cell lines. D0 is calculated as the dose required to reduce the cell
surviving fraction from: 1.0 to 0.37 (for the first decade of cell kill-
ing), 0.1 to 0.037 (for the second decade of cell killing), 0.01 to 0.0037
(for the third decade of cell killing), and so on, using historic  and 
parameters.36 Large symbols represent D0-values derived from the
multi-target formalism.
FIG. 4: Plot of D0, derived from LQ parameters, as a function of the
decade of cell killing in which D0 is derived for human prostate (6
cancer and 1 normal) cell lines. D0 is calculated as the dose required
to reduce the cell surviving fraction from: 1.0 to 0.37 (for the first
decade of cell killing), 0.1 to 0.037 (for the second decade of cell
killing), 0.01 to 0.0037 (for the third decade of cell killing), and so on,
using historic  and  parameters.37,38 Large symbols represent
D0-values derived from the multi-target formalism.
FIG. 5: Plot of D0, derived from LQ parameters, against the decade of
cell killing in which D0 is derived for human glioblastoma, neuro-
blastoma, and prostate cell lines. Symbols representing pooled data
from Figures 2-4 are superimposed on fitted curves from historical
data for glioblastoma (dotted line)41, neuroblastoma (dashed line)31, 43
and prostate (solid line)44 cell lines. Large symbols represent
D0-values derived from the multi-target formalism from cell survival
data for each group of cell lines.36-38 Error bars represent the standard
error of the mean for each set of pooled data.
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Similarly, D0 declined from 1.85 ± 0.38 to 0.68 ± 0.04 Gy in
the neuroblastoma cell lines (Figure 3). For the prostate cell
lines, D0 decreased from 2.28 ± 0.23 Gy at high levels of cell
survival to 0.81 ± 0.08 Gy at high levels of cell killing (Figure
4). In all cases, D0-values derived from the multi-target for-
malism were significantly higher than those obtained from
the LQ model at a cell survival level of 10-10 (P  0.0023).
The resulting transition doses obtained from D0-values de-
rived from the LQ model were found to be up to 3-fold
higher than those determined from the multi-target formal-
ism. In the glioblastoma, neuroblastoma and prostate cell
lines, the transition doses were found to increase from 7.84 ±
0.56, 8.91 ± 1.20 and 6.55 ± 0.91 Gy to 26.84 ± 2.83, 23.95 ±
2.03 and 22.29 ± 2.31 Gy, respectively.
Discussion
In this study, D0-values obtained from the multi-target for-
malism fall within the range of those reported in in vitro and
in vivo studies using cells originating from a wide variety of
malignancies.1,28-35 Although there were changes in
rank-order between D0-values obtained from the multi-target
and linear-quadratic (LQ) formalisms, they did not signifi-
cantly affect the variations of D0 within each group of cell
lines (Table 1). Specifically, the coefficients of variation in D0
for the glioblastoma, neuroblastoma and prostate cell lines
emerged as 30.32, 13.88 and 18% for the multi-target model,
and 23.86, 12.04 and 26.76% for the LQ model, respectively
(Table 1). The significant variations demonstrated in D0 at
high levels of cell killing contrast with early suggestions that
D0 for cells from human tumors of varying radiocurability do
not differ significantly.28, 40 These findings may have im-
portant implications for the prediction of cellular responses at
high radiation absorbed doses for which measurement of cell
inactivation is not feasible.
The dependence of D0 on the extent of cell killing, and
therefore total absorbed dose, demonstrated here suggests
that D0-values as obtained from in vitro experiments (usually
from 2-3 logs of cell killing) or from small in situ data sets
may be overestimated. With the exception of highly radio-
sensitive ataxia telangiectasia cells, typical D0-values for tu-
mor and normal cells have been found to range between ~0.9
and 3.7 Gy.1, 28-35 To test the strength of our model for ex-
trapolating radiosensitivity at doses for which in vitro ex-
perimental data cannot be generated, the data presented in
Figures 2-4 were pooled and compared with D0-values simi-
larly derived from  and  parameters that were reported for
glioblastoma, neuroblastoma, and prostate cell lines in other
historic studies.41-44 The comparison is shown in Figure 5 and
illustrates that the current and historical data are congruent.
However, the significant reduction seen in D0 as the level of
cell killing increases warrants a re-evaluation of the capacity
of the LQ model to predict tissue response at high doses, on
the basis of D0-values derived from the LQ model at cell sur-
vival rates of ~1010, instead of those obtained from the mul-
ti-target model. For each group of cell lines, the values of D0
extrapolated in the 10th log of cell killing from the LQ model
were again found to be significantly lower than those ob-
tained from the multi-target model. This may have a direct
impact on radiotherapy using large fractional doses.
To fully realise the strength of the LQ model in predicting
radiation response at doses high enough to yield cell surviving
fractions of the order of 10-10, the dose protraction shift pa-
rameter, 7, 10, should be calculated using values of D0 from
the LQ model (Equations 2-4) corresponding to such high
levels of cell killing as defined in Equation (7). High values of
D0 as typically obtained from in vitro measurements or lim-
ited in vivo data can result in large -values, and corre-
spondingly lead to low values of the transition dose D*.7, 10, 13
To illustrate this, D0-values were derived from cell survival
data using the multi-target model, as defined in Equation (1),
and used to calculate  and D*.7,10 They were then compared
with those obtained from D0-values derived within the 10th
log of cell killing using the LQ model. On average, D0-values
obtained from the LQ model were found to be about half of
those determined from the multi-target model (Table 1) or
those typically reported in the literature.1, 28-35 This reduction
resulted in a corresponding decrease of 64 – 74% in the shift
parameter to values of 0.039 ± 0.003, 0.043 ± 0.004 and 0.049 ±
0.007 Gy-1 for the glioblastoma, neuroblastoma and prostate
cell lines, respectively (Table 1).
The decline in the dose protraction shift parameter translates
to ~3-fold increase in the transition dose. The D*-values ob-
tained here from the multi-target formalism are comparable
to those reported by other investigators.7,10 With the excep-
tion of lymphomas and oat cell carcinomas, for which D*
values were very low, average D* values of 7.8, 5.6, 6.7 and 5.9
Gy were determined for glioblastomas, squamous cell carci-
nomas, melanomas and adenocarcinomas, respectively.7 In
contrast, D*-values derived from the LQ model in the 10th log
of cell killing are consistent with the suggestion that this
formalism is appropriate for assessing tissue response to
hypofractionated and stereotactic radiotherapy employing
high fractional doses.4,16 These results demonstrate that the
radiation absorbed dose at which the LQ model might not be
appropriate for predicting tissue response could be much
higher than generally thought. These data further suggest
that the LQ model can be used for fractionated radiotherapy
employing doses of the order of 20 Gy per fraction.
Conclusion
Using the well-defined  and  parameters of the LQ model
for human glioblastoma, neuroblastoma, and prostate cell
lines, we provide evidence that the D0 parameter varies sig-
nificantly with the level of cell killing. D0-values derived
within the first few logs of cell killing are about 2-fold higher
than those obtained at levels of cell killing of the order of 10
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logs. It is further demonstrated that values of the dose pro-
traction shift parameter, , are much smaller than initially
thought, and can result in significantly larger transition doses
D*. These findings show that the LQ model may be used for
fractionated radiotherapy employing large doses per fraction.
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